$10.830
-0.040 (-0.37%)收盘时
价格预测
在 App 中打开以解锁更长周期的预测。
该买入 Narragansett Bancorp, Inc. Common Stock 股票吗?
Sanara Medtech Inc (SMTI) is currently not a strong buy due to its low RSI of 16.595, indicating oversold conditions, and a recent downgrade by analysts to Hold, suggesting caution. The stock is trading at $31.68, which is 80.3% of its 52-week range, indicating it is near its high. The upcoming earnings report on November 11, 2026, with an estimated EPS of $0.06, could be a catalyst for movement. However, the risk of regulatory delays in the MiMed acquisition could negatively impact the stock, as indicated by the recent news of extended FTC reviews.
NARA 股价于 Friday 收于 $10.83,此前下跌 -0.37%
Narragansett Bancorp, Inc. Common Stock (NARA) last closed at $10.8299999, losing -0.37%. These facts feed the 1-day and 1-week NARA price prediction above.
预测驱动因素
Narragansett Bancorp, Inc. Common Stock(NARA)的预测驱动因素综合了相似的图表形态、季节性与移动平均线。
Seasonality
Bullish
NARA 季节性分析
相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。